Durelli L - Search Results

1

Autoimmune events during interferon beta-1b treatment for multiple sclerosis.

Durelli L, Ferrero B, Oggero A, Verdun E, Bongioanni MR, Gentile E, Isoardo GL, Ricci A, Rota E, Bergamasco B, Durazzo M, Saracco G, Biava MA, Brossa PC, Giorda L, Pagni R, Aimo G. Durelli L, et al. J Neurol Sci. 1999 Jan 1;162(1):74-83. doi: 10.1016/s0022-510x(98)00299-8. J Neurol Sci. 1999. PMID: 10064173 Clinical Trial.

2

High-dose, frequently administered interferon beta therapy for relapsing-remitting multiple sclerosis must be maintained over the long term: the interferon beta dose-reduction study.

Barbero P, Verdun E, Bergui M, Pipieri A, Clerico M, Cucci A, Ricci A, Bergamasco B, Durelli L. Barbero P, et al. Among authors: durelli l. J Neurol Sci. 2004 Jul 15;222(1-2):13-9. doi: 10.1016/j.jns.2004.03.023. J Neurol Sci. 2004. PMID: 15240190 Clinical Trial.

3

Anti-interferon antibodies in multiple sclerosis. Molecular basis and their impact on clinical efficacy.

Durelli L, Ricci A. Durelli L, et al. Front Biosci. 2004 Sep 1;9:2192-204. doi: 10.2741/1329. Front Biosci. 2004. PMID: 15353281 Review.

4

Interferon alpha-2a treatment of relapsing-remitting multiple sclerosis: disease activity resumes after stopping treatment.

Durelli L, Bongioanni MR, Ferrero B, Ferri R, Imperiale D, Bradac GB, Bergui M, Geuna M, Bergamini L, Bergamasco B. Durelli L, et al. Neurology. 1996 Jul;47(1):123-9. doi: 10.1212/wnl.47.1.123. Neurology. 1996. PMID: 8710065 Clinical Trial.

5

Systemic high-dose recombinant-alpha-2a-interferon therapy modulates lymphokine production in multiple sclerosis.

Bongioanni MR, Durelli L, Ferrero B, Imperiale D, Oggero A, Verdun E, Aimo G, Pagni R, Geuna M, Bergamasco B. Bongioanni MR, et al. Among authors: durelli l. J Neurol Sci. 1996 Nov;143(1-2):91-9. doi: 10.1016/s0022-510x(96)00176-1. J Neurol Sci. 1996. PMID: 8981304 Clinical Trial.

6

Long term recombinant interferon alpha treatment in MS with special emphasis to side effects.

Durelli L, Bongioanni MR, Ferrero B, Imperiale D, Verdun E, Oggero A, Gentile E, Bradac GB, Bergui M, Bergamini L, Bergamasco B. Durelli L, et al. Mult Scler. 1996 Jul;1(6):366-71. doi: 10.1177/135245859600100617. Mult Scler. 1996. PMID: 9345419 Clinical Trial.

7

Interferon treatment for multiple sclerosis: autoimmune complications may be lethal.

Durelli L, Bongioanni MR, Ferrero B, Oggero A, Marzano A, Rizzetto M. Durelli L, et al. Neurology. 1998 Feb;50(2):570-1. doi: 10.1212/wnl.50.2.570. Neurology. 1998. PMID: 9484407 No abstract available.

8

Does high-dose interferon beta-1b improve clinical response in more severely disabled multiple sclerosis patients?

Durelli L, Oggero A, Verdun E, Isoardo G, Ricci A, Barbero P, Bergamasco B. Durelli L, et al. J Neurol Sci. 2000 Sep 1;178(1):37-41. doi: 10.1016/s0022-510x(00)00361-0. J Neurol Sci. 2000. PMID: 11018247 Clinical Trial.

9

Thyroid function and autoimmunity during interferon beta-1b treatment: a multicenter prospective study.

Durelli L, Ferrero B, Oggero A, Verdun E, Ghezzi A, Montanari E, Zaffaroni M; Betaferon Safety Trial Study Group. Durelli L, et al. J Clin Endocrinol Metab. 2001 Aug;86(8):3525-32. doi: 10.1210/jcem.86.8.7721. J Clin Endocrinol Metab. 2001. PMID: 11502774 Clinical Trial.

10

Interferon-beta dose and efficacy: the OPTIMS study.

Durelli L, Oggero A, Verdun E, Barbero P, Pipieri A, Isoardo G, Ricci A, Clerico M, Bradac G, Bergamasco B, Bergui M. Durelli L, et al. Neurol Sci. 2001 Apr;22(2):201-3. doi: 10.1007/s100720170024. Neurol Sci. 2001. PMID: 11603627

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

158 results

Search Page

Filters